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ABSTRACT (words: 335) 
The recent identification of the pancreas major zymogen granule membrane glycoprotein 2 
(MZGP2) as the major autoantigen of pancreatic autoantibody (PAB) has led to the 
appreciation of anti-MZGP2 antibodies as specific markers of Crohn’s disease (CrD). We 
have recently developed new, robust, highly sensitive and specific IgA and IgG anti-MZGP2 
antibody ELISAs and assessed their clinical relevance in the largest inflammatory bowel 
disease (IBD) cohort tested to date for anti-MZGP2 antibodies.  In contrast to currently 
available anti-MZGP2 ELISAs, the new QUANTA Lite® MZGP2 ELISA (INOVA Diagnostics, 
San Diego, CA) utilizes the eukaryotically-expressed specific isoform 4 of human GP2 
UniProtKB: P55259. A total of 832 sera were studied including 617 consecutive IBD patients 
(323 CrD and 294 UC) under regular follow-up in a tertiary centre, 112 patients with various 
diseases, and 103 healthy blood donors. The new ELISA’s calculated AUC was 0.5968, 95% 
CI (0.5552, 0.6383) for IgA anti-MZGP2 [CD vs non-CD (UC plus controls)] and 0.6236, 95% 
CI (0.5813, 0.6659) for IgG anti-MZGP2. The sensitivity of IgA anti-MZGP2 for CrD in the 
IBD population was 15% and the specificity was 98% (95, 99), while the sensitivity and 
specificity of IgG anti-MZGP2 was 27% and 97%. IgA and IgG anti-MZGP2 combined testing 
led to a sensitivity of 31% and specificity of 96%. Positivity for either ASCA (IgA or IgG) or 
anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and specificity of 84% (79, 
89). Of clinical relevance, IgA anti- MZGP2 antibodies were more prevalent in patients with 
early disease onset (Montreal classification A1, p=0.011), while patients with localised 
colonic disease were less likely to be IgG anti-MZGP2 positive. Anti-MZGP2 positive 
patients more frequently had extensive disease with ileal involvement and stricture 
formation. Patients with longer disease duration were more likely to have IgG anti-MZGP2 or 
IgA ASCA antibodies. In conclusion, the new IgA and IgG anti-MZGP2 antibody ELISAs 
allow accurate autoantibody determination, and can be used as a tool to study the clinical 
significance and utility of these autoantibodies in patients with IBD. 
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INTRODUCTION 
The exact mechanisms responsible for the induction of Crohn’s disease (CrD) as well as 
ulcerative colitis (UC), the other form of inflammatory bowel disease (IBD), remain poorly 
understood 1-4. Both diseases are characterised by antibody seropositivity against distinct 
antigens, which complement the endoscopic and histological examinations used for the 
prompt diagnosis of patients with suspected IBD 5, 6.  
The most widely used antibody marker for CrD is anti-Saccharomyces cerevisiae antibody 
(ASCA), while UC is characterized by the presence of anti-neutrophil cytoplasmic antibodies 
(ANCA) showing an atypical perinuclear (pANCA) pattern by indirect immunofluorescence 
assay (IFA) 5, 6. While most other antibody markers failed to meet demanding clinical needs, 
pancreatic autoantibody (PAB) has emerged as potentially diagnostically and clinically 
meaningful marker 7. Antigen-specific PABs against exocrine pancreas are present in 20-
30% of patients with CrD, but in less than 2-9% of patients with UC, and in very few patients 
with non-IBD related pathology 8, 9. The recent identification of the major zymogen 
glycoprotein 2 (MZGP2) as the primary autoantigen of PAB 10, has prompted the 
development of  ELISAs or IFA techniques to allow the proper detection of anti-MZGP2 
PABs in routine practice 11, 12.  Rodent pancreatic tissue or GP2- over-expressed cell-lines 
have been used as substrates to test for GP2-specific PABs by IFA, but because IFA 
procedures are labor-intensive, time-consuming, and require experienced operators, 
laboratories  prefer to use ELISA-based assays 7, 10-19. ELISA testing for anti-MZGP2 
antibodies has recently become available 11, but the assay is not FDA-approved for in vitro 
diagnostic use in the USA.  In addition, the performance characteristics of these test 
systems have only been compared to those obtained by in-house assays used for research 
protocols in a small number of European Institutions 7, 18.  
The aim of the present study was to develop new robust and highly sensitive and 
specific anti-MZGP2 antibody ELISAs for commercial use. The new ELISAs for the accurate 
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determination of IgA or IgG anti-MZGP2 have been developed and tested using sera from 
617 patients with IBD, including 323 patients with CrD and 294 patients with UC, as well as 
215 pathological and normal controls.  The newly developed ELISAs not only allowed better 
assessment of the diagnostic significance of anti-MZGP2 antibodies, but also gave us the 
opportunity to investigate the clinical significance of these autoantibodies and their relevance 
to distinct clinical phenotypes.  
 
PATIENTS AND METHODS 
Patients 
Six hundred seventeen consecutive patients with a diagnosis of IBD (CrD 323, female/male 
176/147, age 40±14.3, disease duration 14 years IQR[7,22]; UC 294, female/male 141/153, 
age 48.7±15.7, disease duration 14 years IQR[6,25]), under regular follow up in a tertiary 
centre (University College London Hospitals, United Kingdom) were included in this study.  
The IBD patient characteristics are presented in Table 1.The IBD diagnosis was based on 
current standard clinical, radiological, endoscopic, and histological criteria (Lennard-Jones 
criteria 20). Demographics and disease information including age at study, age at diagnosis, 
disease duration, location/extent and behaviour were extracted from a prospectively updated 
IBD database. The disease phenotypes were determined according to the Montreal 
classification21 . 
Additionally, 112 patients with various diseases were studied as pathological controls, 
including serum samples from patients with the following diagnoses: celiac disease (n=20);  
chronic pancreatitis (n=19); diabetes mellitus  (n=20); primary sclerosing cholangitis (n-21); 
primary biliary cirrhosis (n=10); autoimmune hepatitis/PSC overlap syndrome (n=6); chronic 
hepatitis B (n=8); and chronic hepatitis C (n=8}. Finally, 103 randomly selected blood donors 
(age17-60, sex female/male 64/39) were also studied as normal controls. Investigators 
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performing tests were blinded to the patients’ exact diagnoses. The study was conducted in 
accordance with the Helsinki declaration and approved by the local ethics committees. 
Written informed consent was obtained from each individual. All sera had been stored at 
−20°C before analysis.  
 
IgA and IgG ASCA testing by ELISA 
Determination of IgA and IgG ASCA antibodies were determined by an FDA-cleared ELISA 
(QUANTA LIte® ASCA IgG and ASCA IgA, INOVA Diagnostics) following the manufacturer’s 
protocol.  A cut off for positivity was set at 25 U (arbitrary units) as recommended by the 
manufacturer. 
 
IgG and IgA anti-MZGP2 antibody testing by ELISA  
MZGP2 IgG and IgA antibodies were detected by novel ELISAs (INOVA Diagnostics, 
Research Use Only) utilizing human recombinant MZGP2, isoform 4 antigen UniProtKB: 
P55259.  Briefly, 100 µLs of pre-diluted control and diluted patient sera (1:100) were added 
to separate wells of MZGP2 antigen-coated polystyrene microwells and incubated for 30 min 
at room temperature. Unbound sample was then washed away and peroxidase-conjugated 
goat anti-human IgG antibody or anti-human IgA antibody was added to each well. After 
another incubation and washing steps, the remaining enzyme activity was measured by 
adding tetramethylbenzidine chromogenic substrate for 30 minutes. Stop solution (H2SO4) 
was added to terminate the reaction and absorbance read at 450/620 nm.  Results, 
expressed in arbitrary units (U), were calculated in reference to a kit-provided calibrator.  
Results ≥ 25 U were interpreted as positive   
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ANCA testing by IFA 
ANCA for IgG antibodies were evaluated by indirect immunofluorescence using 
commercially available human neutrophil slides (Nova LiteTM, INOVA Diagnostics). Briefly, 
samples were diluted at 1:20 and tested in accordance with the manufacturer’s instructions 
on ethanol- and formalin-fixed human neutrophil substrate slides. Results were reported as 
P-ANCA  if a perinuclear pattern was observed on ethanol and granular cytoplasmic on 
formalin slides, C-ANCA if both ethanol and formalin slides resulted in a cytoplasmic pattern,  
and "atypical" ANCA if the pattern was perinuclear on ethanol and negative on the formalin 
fixed slide. 
 
Pancreatic Antibodies (PAB) by IFA   
Pancreatic antibodies (PAB) were detected by IFA on monkey pancreas tissue (NOVA 
LiteTM, INOVA Diagnostics) using sera at a 1:20 dilution and primate-absorbed goat anti-
human FITC conjugate.     
 
Statistical Methods 
Variables were tested for normality with the Kolmogorov-Smirnov test. Age is presented as 
mean and standard deviation (SD). Non-parametric continuous variables including ASCA 
and anti-MZGP2 titres are given as median and interquartile range (IQR). The report of the 
atypical ANCA is qualitative (positive or negative) based on immunofluorescence review by 
one of the authors (DPB). The cut off for anti-MZGP2 IgA and IgG assays was calculated by 
plotting a receiver operator characteristic (ROC) curve by using the test results of the 
patients with CrD versus controls (UC, healthy, other pathological controls). The area under 
the curve (AUC) values are followed by a 95% confidence interval (CI). The diagnostic value 
of ASCA, anti-MZGP2 and atypical ANCA for the IBD population was assessed by cross 
tabulation and calculation of sensitivity, specificity, positive and negative predictive values, 
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all presented as percentages followed by 95% CI. The clinical significance of the different 
antibodies was studied with chi-square tests for every clinical variable (2x2 tables) and the 
results are presented as odds ratios with 95% CI and p values. Associations between 
variables found on univariate analysis to have statistically significant (p<0.05) high 
prevalence in patients testing positive for individual autoantibodies or autoantibody 
combinations were further tested by loglinear regression. Comparisons in titre medians 
between different diseases or disease subgroups were performed using the non-parametric 
Mann Whitney or Kruskal Wallis tests. Comparisons of parametric variables (ie age) were 
performed using the upaired t-test. Cross tabulation and loglinear analysis was performed 
using SPSS (SPSS Inc., Chicago, Illinois, USA) software. Prizm software (by GraphPad 
Software Inc., La Jolla, California, USA) was used for ROC curve plotting, antibody titre 
comparisons and figures. 
 
RESULTS 
Diagnostic accuracy of serological markers  
Venn diagrams depicting numbers of CrD or UC cases showing individual reactivities are 
shown in Figure 1. Scatter plots of anti-MZGP2 antibody reactivities (IgG or IgA) in patients 
with CrD, UC, pathological, and normal controls are shown in Figure 2. The ROC curves for 
anti-MZGP2 IgA and IgG assays (CrD vs controls) are also presented as inserts in Figure 2. 
The calculated AUC was 0.5982, 95% CI (0.5567, 0.6398) for IgA anti-MZGP2 [CD vs non-
CD (UC and controls)] and 0.6240, 95% CI (0.5817, 0.6662) for IgG anti-MZGP2. The 
sensitivity, specificity and likelihood ratio for different cut offs of anti-MZGP2 are presented in 
Table 2 (for CrD vs non-CrD cohorts, including UC, pathological and normal controls) and in 
Table 3 (for CrD vs UC), respectively.  
The sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% (11, 19) and the 
specificity was 98% (95, 99), while the sensitivity of IgG anti-MZGP2 for CD was 27% (22, 
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32) and the specificity was 97% (94-98) using the manufacturer’s cut-off set at 25 U. In 
comparison, the sensitivity of IgA and IgG ASCA for CrD was 47% (41, 52) and 66% (61, 
71), respectively, while the specificity was 95% (92, 97) and 90% (86, 93), respectively for 
CrD vs UC. The combination of positive IgA and IgG ASCA testing increased the sensitivity 
to 71% (66, 76) but reduced the specificity to 87% (83,91). Positivity for either ASCA (IgA or 
IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and specificity of 84% 
(79, 89).  
The presence of any one of the autoantibodies (ASCA IgA, ASCA IgG, MZGP2 IgA, MZGP2 
IgG) yielded the highest sensitivity at 75% (70, 80), but reduced specificity to 84% (79, 89).  
In contrast, while only 7% sensitive, the presence of all four autoantibodies (ASCA IgA, 
ASCA IgG, MZGP2 IgA, MZGP2 IgG) in 23 individuals (Table 4 and Figure 1) was 100% 
specific for CrD, being negative in all 294 patients with ulcerative colitis.  Dual positivity for 
MZGP2 IgA and IgG was slightly less specific at 99% (11% sensitivity), followed by dual 
positivity for ASCA IgA and IgG at 98% specificity and 42% sensitivity and single IgA 
MZGP2 positivity with a specificity of 98% and a sensitivity of 15%.  
The sensitivity of IgG atypical (x)ANCA testing for UC in the IBD population was 36% (31, 
42) and the specificity was 91% (87,94). Sensitivity, specificity, negative, and positive 
predictive values are presented for all autoantibodies and their combinations in Table 4. 
As expected, ASCA and anti-MZGP2 antibody titres were higher in CrD compared to UC; the 
difference of the median titres for all antibody reactivities between CrD and UC was 
statistically significant (Mann Whitney, anti-MZGP2 IgA p= 0.0045, anti-MZGP2 IgG 
p<0.0001, ASCA IgA p<0.0001 and ASCA IgG p<0.0001). Figure 3 shows ASCA levels in 
IgA or IgG anti-MZGP2 antibody positive and negative patients with CrD. 
 
Clinical Significance of Antibody  
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Table 5 presents the associations between the autoantibodies and different disease 
characteristics. IgA anti-MZGP2 antibodies were more prevalent in patients with early 
disease onset (A1< 16 years, OR: 2.3 [1.2, 4.4], p=0.011). Patients positive for IgG ASCA 
were younger when compared to negative CrDs (mean age 22.92 +/- 0.62 vs. 28.02 +/- 1.44, 
upaired t test, p=0.0002) and were less likely to have late disease onset (A3) (p=0.003 for 
IgG and p=0.026 for IgA). Patients with A3 disease onset had lower titres for IgA or IgG 
ASCA (median IgA ASCA titre for A1: 23.6, A2: 23.4, A3: 9, p=0.002, median IgG ASCA titre 
for A1:42, A2: 45.5, A3: 16.8, p= 0.001). Also, IgA anti-MZGP2 titres were higher in younger 
patients (median IgA anti-MZGP2 titre for A1: 7.4, A2: 4.3, A3: 3.8, p=0.04). 
Patients positive for IgG anti-MZGP2 or (IgA or IgG) ASCA were more likely to have 
extensive CrD with ileal involvement (OR: 2.3, 1.7, 1.9, respectively). The presence of both 
(IgA or IgG) anti-MZGP2 and (IgA or IgG) ASCA increased the OR for extensive disease 
(L3) to 2.8 (1.5, 5.2). Patients with localised colonic disease were less likely to be positive for 
these antibodies; IgA ASCA, IgG ASCA and IgG anti-MZGP2 titres were also lower in these 
patients and higher in patients with extensive disease (median IgA ASCA titre for L1: 24.05, 
L2: 12.2, L3: 26.6, L4: 15.1, p=0.02; median IgG ASCA titre for L1: 46.95, L2: 16.8, L3: 49.1, 
L4: 54.5, p=0.001; median IgG anti-MZGP2 titres for L1: 4.55, L2: 3.7, L3: 7.4 0.156, L4: 3.7, 
p=0.046, (Figure 4). 
Stricturing disease (B2) was more likely in patients tested positive for IgG ASCA (OR:2.3 
[1.3,4]), while the presence of both (IgA or IgG) anti-MZGP2 and (IgA or IgG) ASCA 
increased the OR for B2 to 3.1 (1.5, 6.3). Antibody titres were also higher in B2 in 
comparison to B1, B3 (median ASCA IgA titre for B1: 17.3, B2: 29.1, B3: 25.35, p=0.007, 
median IgG ASCA titre for B1: 35.2, B2: 53.7, B3: 45.2, p=0.033). IgA ASCA, IgG ASCA or 
(IgA, IgG) anti-MZGP2 were less prevalent in patients with inflammatory behaviour (B1).  
Patients with longer disease duration were more likely to have IgG anti-MZGP2 (difference in 
medians: 2 years), or IgA ASCA antibodies (difference in medians: 5.5 years). 
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Atypical ANCA were not associated with sex, age of onset, disease duration, disease extent 
or the requirement for colectomy and stoma formation in UC patients. UC patients positive 
for atypical ANCA though, were older on disease onset (mean age: 32.35 vs. 25.67, p=0.02) 
and had longer disease duration (median duration 16.5 vs. 12 , p= 0.03) when compared to 
positive patients with CrD. 
Of the 13 ulcerative colitis patients positive for MZGP2 IgG and/or IgA, 2 were also positive 
for both ASCA IgG , ASCA IgA, and both IgG and IgA pancreatic antibodies by IFA.   Four 
other patients showed moderate to strong PAB (IgG and/or IgA) by IFA.  Of the 5 normal 
donors found positive for MZGP2 IgG, 1 was ASCA IgG and IgA positive with1-2+ IgA PAB, 
and 3 others showed 1-2+ IgA PAB and nonspecific IgG PAB.   The one very strong positive 
chronic pancreatic patient had no clinical features identified which distinguished them from 
the other chronic pancreatitis patients.   
 
DISCUSSION 
In the present study, we report development of two robust, highly-specific ELISAs for the 
detection of IgA and IgG anti-MZGP2 PABs. Using these ELISAs, we have detected anti-
MZGP2 antibodies in 31% of patients with CrD and 4% of UC patients. Among the reactive 
CrD patients, 27% and 15% showed IgG or IgA anti-MZGP2 reactivity, while reactivity to 
both isotypes was concurrently present in 11% of the CrD patients, but in just 1% of patients 
with UC.  
Cumulatively, the new ELISAs demonstrate enhanced sensitivity and superior specificity for 
CrD within IBD compared to commercial anti-MZGP2 ELISAs currently available (GA). A 
recent study using GA’s ELISA tested 3 cohorts – two from Germany and one from our 
centre – and reported an overall (IgA or IgG) anti-MZGP2 sensitivity and specificity of 30.2% 
and 91%, respectively 13. Additional testing on a Belgium cohort using the GA ELISA has 
showed anti-MZGP2 antibodies in 21% of CrD patients and 9% of UC patients 14. 
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Interestingly, other studies reported GA ELISA anti-MZGP2 antibody reactivity in up to 22% 
of patients with UC  10-12, 15-19. The low specificity reported for this assay raises significant  
concerns  for the diagnostic utility of this test and its incorporation into routine testing of 
individuals assessed for IBD. The lower sensitivity and specificity of the GA ELISA in the 
Belgian cohorts has been attributed to the difference in the geographic origin of the patients 
and/or the selection criteria for involvement in the studies 22. Methodological issues were not 
raised, as both studies have used the GA ELISA kit and were performed by exceedingly 
qualified research laboratories 11, 22.  
The majority of studies have agreed upon the fact that most IgA anti-MZGP2 antibody 
positive CrD patients have concurrent IgG antibodies against the same antigen 10, 11, 13-16. In 
the present study, we also noted that IgA anti-MZGP2 antibody positivity marginally 
increases the over-all sensitivity of the test, as only 4.3% (14/323, Figure 1) of the IgG anti-
MZGP2 seropositive cases had only IgA anti-MZGP2 antibodies. This finding points towards 
the limited diagnostic utility of the IgA antibodies, but does not exclude their clinical 
relevance, as there are several clinical correlates associated with the presence of IgA anti-
MZGP2 only (see Table 3).  
At a first glance, ASCA (IgA or IgG) remain the most sensitive antibody tests for CrD with a 
sensitivity of 71% compared to 31% for anti-MZGP2 (IgA or IgG) 6. However, ASCA testing 
shows the lowest specificity for CrD in IBD (87%), while that of anti-MZGP2 is much higher 
(96%). This difference in the overall specificity is clinically significant.  The sensitivity of anti-
MZGP2 for CrD in IBD could be even higher if the cut off was set to less stringent specificity. 
For example if a 94% specificity was targeted, the cut off could be lowered to 15 U for both 
IgA and IgG anti-MZGP2 and the resulting sensitivity of anti-MZGP2 for CrD could reach as 
much as 24% for IgA and 35% for IgG anti-MZGP2 (Table 2). Studies directly investigating 
the performance of the two assays in well-defined IBD serum samples, pre-characterised as 
‘equivocal’, low, or moderate level seropositive sera from IBD patients and controls are 
needed to clarify this topic. The relatively low specificity of ASCA for CrD in IBD is a well-
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described feature and is one of the greatest limitations of this test 6. Nevertheless, 
simultaneous detection of anti-MZGP2 and ASCA (of any isotype) is practically absent in 
patients with UC. The assays can be used to help “rule out” UC.   In other words, if a patient 
with a suspicion of IBD is seropositive for both ASCA and anti-MZGP2, they are unlikely to 
have UC (PPV for CD: 100%). Also, 12 out of 87 (14%) CrD ASCA negative patients had 
anti-MZGP2 antibodies, which could suggest that 14% of clinically suspicious individuals 
(who were reliant on ASCA positivity for a firm diagnosis of CrD), may have gone unnoticed 
if anti-MZGP2 antibody testing was not ordered.  The detection of the MZGP2 antibodies can 
alert the clinician to the potential presence of CrD and suggest additional evaluation of the 
patient.  
 There is no doubt that the development of these new assays will promote more research on 
the diagnostic and clinical value of MZGP2 antibodies in IBD 7, 18. Using our new assays, 
together with the wealth of detailed clinical data available on the study cohort patients, we 
have found several associations between patients with IgA or IgG anti-MZGP2 antibody 
reactivities and clinical parameters. Some of these associations have been previously 
described and are confirmed with our new assay, while others are newly described 10, 11, 14-19. 
Using earlier ELISAs, we have found that anti-MZGP2 antibody reactivity is a characteristic 
feature of patients with ileocolonic location 13, 16.  We have been able to replicate this finding 
using the INOVA anti-MZGP2 ELISAs. We also noted in the past that younger age (A1) at 
diagnosis connotes the characteristic feature of a higher prevalence of anti-MZGP2 
antibodies within this group compared to patients diagnosed at older age (A2 and A3) 13. 
This finding has also been confirmed by the new ELISA testing. Finally, using the GA ELISA, 
anti-MZGP2 antibodies have been able to identify patients with stricturing disease. 
Intriguingly, stricturing disease (B2) was more likely (OD: 3.1) in patients testing positive for 
the presence of ASCA or anti-MZGP2 by the new ELISA, further underlined the notion that 
simultaneous testing of these autoantibodies may be of help to treating physicians. 
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Our study has revealed previously unnoticed associations.  For example, patients positive 
for IgG anti-MZGP2 were more likely to have extensive CrD with ileal involvement, which 
was also the case for IgA or IgG ASCA (OR: 2.3, 1.7, 1.9, respectively). As this ELISA uses 
a new form of the MZGP2 protein (Isoform 4) as well as a new assay configuration, the 
clinical associations reported here must be validated externally.  Anti-MZGP2 antibodies 
have recently been determined by a commercial IFA using GP2-overexpressing cell lines 
(EUROIMUNN)12, however the performance relative to the new ELISAs is unknown.  In 
conclusion, our new ELISA permits the accurate detection of GP2 PAB-specific 
autoantibodies with high efficiency. Though firm conclusions regarding the clinical utility of 
anti-MZGP2 antibodies cannot be reached at this time, we are confident that the present 
data mirror results that could be obtained by independent investigators. Significantly, our 
study enrolled the largest number of CrD and UC patients investigated thus far in a single 
centre and supports the strength of the study and its conclusions. Some of the findings 
published in the past have included cumulative data merged from cohorts of various centres, 
and this may explain inconsistencies amongst publications 7, 18. We suggest that testing of 
large series of uniformly collected and selected serum samples from independent cohorts, 
as was done in the present study, will provide insight into  the diagnostic and clinical value of 
these autoantibodies, in combination or in isolation,  for the more effective assessment and 
management of patients. 
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Legends to the Figures 
Figure 1. Venn diagrams of individual IgA or IgG anti-Saccharomyces cerevisiae antibody 
(ASCA) and anti-major zymogen granule membrane glycoprotein 2 (MZGP2) serum 
antibody reactivity of patients with Crohn’s disease (CD) and ulcerative colitis (UC) 
 
Figure 2. Anti-MZGP2 antibody reactivity(IgG, left and IgA right) in 323 patients with Crohn's 
disease (CrD), 294 with ulcerative colitis (UC) patients and in pathological controls including 
patients with coeliac disease (n=20);  chronic pancreatitis (n=19); diabetes mellitus, DM  
(n=20); primary biliary cirrhosis, PBC (n=10); primary sclerosing cholangitis, PSC (n-21); 
autoimmune hepatitis(AIH)/PSC overlap syndrome (n=6); chronic viral hepatitis (viral hep) 
(chronic viral hepatitis  B (n=8); and chronic viral hepatiis C (n=8); Normal controls consisted 
of 103 randomly selected blood donors. 
 
Figure 3.  ASCA antibody reactivity in anti-MZGP2 antibody positive (n=98) and anti-MZGP2 
antibody negative (n=225) patients with Crohn’s disease  
 
Figure 4. Scatter plot analysis of individual antibody reactivities seen in 323 patients with 
Crohn’s disease stratified in accordance to disease location (L1-L4, Montreal classification). 
A scatter plot for IgA anti-MZGP2 was not included because comparison of titres did not 
show statistically significant differences. 
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Table 1. Major demographic and clinical characteristics of the 323 Crohn’s disease (CrD) 
and 294 ulcerative colitis (UC) patients enrolled in the study. 
 CrD 
(n=323) 
UC 
(n=294) 
   
Sex (m/f) 147/176,  
(46% / 54%)  
153/141,  
(52%/ 48%) 
Age 40 (±14.3 SD)  48.7 (±15.7SD) 
   
Age at diagnosis  
(years) 
24.7 (±11.7SD) 31.98(±13.9SD) 
Disease Duration 
(years) 
14 (IQR 7.22) 14 (IQR 6,25) 
   
Age  A1:    76 (24%)    
 A2:   214 (66%)   
 A3:    33 (10%)  
   
Location* (L)/ Extent* 
(E) 
L1:    38 (12%) E1:     28 (9%) 
 L2:    53(16%)  E2:   82 (28%) 
 L3:  227 (70%) E3: 184 (63%) 
 L4:      5 (2%)   
   
Behavior *(B) B1:  168 (52%)  
 B2:   83 (26%)   
 B3:    72 (22%)   
 Perianal:   72 (22%)  
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According to Montreal classification A (Age); A1, below 17 years; A2 between 17 and 40 
years; A3, above 40 years; L (Location), L1, ileal; L2, colonic; L3, ileocolonic, and L4, upper 
disease modifier; B1, non-stricturing; B2, structuring; B3, penetrating behavior 
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Table 2. Diagnostic accuracy of anti-MZGP2 antibodies (IgA, IgG) for different cut offs in 
Crohn’s disease versus pathological (including ulcerative colitis) and normal controls. 
Results are presented as sensitivity (% and 95% confidence intervals values), specificity, (% 
and 95% confidence intervals values) and likelihood ratios. 
IgA anti-
MZGP2 
cut off Sensitivity (%) 95% CI Specificity (%) 95%CI Likehood Ratio 
> 10 31.27 26.25% to 36.63% 88.61 85.52% to 91.23% 2.74 
> 15 23.84 19.30% to 28.87% 93.71 91.24% to 95.66% 3.79 
> 20 17.96 13.93% to 22.59% 95.87 93.76% to 97.43% 4.35 
> 25 14.55 10.89% to 18.88% 97.45 95.67% to 98.63% 5.70 
> 30 12.07 8.729% to 16.13% 98.62 97.19% to 99.45% 8.78 
> 40 10.22 7.138% to 14.05% 99.02 97.72% to 99.68% 10.40 
 
IgG anti-
MZGP2 
cut off Sensitivity (%) 95% CI Specificity (%) 95%CI Likehood Ratio 
> 10 39.94 34.56% to 45.51% 89.98 87.04% to 92.45% 3.99 
> 15 34.67 29.49% to 40.14% 93.71 91.24% to 95.66% 5.52 
> 20 30.34 25.37% to 35.67% 95.28 93.07% to 96.96% 6.43 
> 25 26.63 21.88% to 31.80% 96.66 94.71% to 98.04% 7.97 
> 30 25.08 20.44% to 30.17% 97.64 95.92% to 98.78% 10.64 
> 40 22.29 17.87% to 27.23% 98.62 97.19% to 99.45% 16.21 
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Table 3.  Diagnostic accuracy of anti-MZGP2 antibodies (IgA, IgG) for different cut offs in 
Crohn’s disease versus ulcerative colitis. Results are presented as sensitivity (% and 95% 
confidence intervals values), specificity, (% and 95% confidence intervals values) and 
likelihood ratios. 
 IgA 
anti-
MZGP2 
cut off Sensitivity (%) 95% CI Specificity (%) 95%CI Likehood Ratio 
> 11 28.48 23.62% to 33.74% 89.80 85.75% to 93.01% 2.79 
> 15 23.84 19.30% to 28.87% 94.56 91.31% to 96.86% 4.38 
> 20 17.96 13.93% to 22.59% 96.26 93.40% to 98.12% 4.80 
> 25 14.55 10.89% to 18.88% 97.62 95.16% to 99.04% 6.11 
> 30 12.07 8.729% to 16.13% 97.96 95.61% to 99.25% 5.92 
> 40 10.22 7.138% to 14.05% 98.30 96.08% to 99.45% 6.01 
> 50 8.359 5.581% to 11.93% 98.98 97.05% to 99.79% 8.19 
 
IgG anti-
MZGP2 
cut off Sensitivity (%) 95% CI Specificity (%) 95%CI Likehood Ratio 
> 11 39.32 33.96% to 44.88% 89.46 85.37% to 92.72% 3.73 
> 15 34.67 29.49% to 40.14% 93.54 90.09% to 96.06% 5.37 
> 20 30.34 25.37% to 35.67% 94.90 91.72% to 97.12% 5.95 
> 25 26.63 21.88% to 31.80% 96.60 93.83% to 98.36% 7.83 
> 29 25.08 20.44% to 30.17% 96.94 94.27% to 98.59% 8.19 
> 40 22.29 17.87% to 27.23% 98.30 96.08% to 99.45% 13.11 
> 50 19.20 15.05% to 23.92% 98.98 97.05% to 99.79% 18.81 
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Table 4. Summary of sensitivity (% and confidence intervals values), specificity, negative predictive values (NPV) and positive predictive values 
(PPV) of individual antibody reactivities in 323 Crohn’s disease (CrD) and 294 ulcerative colitis (UC) patients.  
 CrD (n=323) 
(positive n)  
UC (n=294) 
(positive n)  
Sens%  Sens CI%  Spec %  Spec CI%  PPV%  NPV%  
IgA anti-MZGP2 pos  48  7  15  11, 19  98  95, 99  87  51  
IgG anti-MZGP2 pos  87  10  27  22, 32  97  94, 98  90  55  
IgA and/or IgG anti-MZGP2 pos  99  13  31  25, 36  96  93, 98  88  56  
IgA and IgG anti-MZGP2 pos  36  4  11  8, 15  99  97, 99  90  50  
IgA ASCA pos  151  14  47  41, 52  95  92, 97  92  62  
IgG ASCA  pos  213  29  66  61, 71  90  86, 93  88  71  
IgA and/or IgG ASCA pos  230  37  71  66, 76  87  83, 91  86  73  
IgA and IgG ASCA pos  134  6  42  36, 47  98  96, 99  96  60  
(IgA or IgG) ASCA and/or (IgA or IgG) 
anti-MZGP2 pos  
242  47  75  70, 80  84  79, 88  84  75  
IgA and IgG ASCA pos and IgA 
and/or IgG anti-MZGP2 pos 
171 0 53 47,59 100 98, 100 100 66 
IgA and IgG ASCA pos and IgA and 
IgG anti-MZGP2 pos  23 
0  7  5, 11  100  99, 100  100  50  
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X-ANCA  (values for UC)  30  106  36  31, 42  91  87, 94  78  61  
IgA or IgG ASCA pos and ANCA neg  214 (66%)  22 (8%)  94  86,98  80  64,91  90  89  
IgA or IgG MZGP2 pos and ANCA 
neg 87 
10 27 
22, 32 97 94, 98 90 55 
 
ANCA.  anti-neutrophil cytoplasmic antibodies; ASCA. anti-Saccharomyces cerevisiae antibody 
25 
 
Table 5. Clinical relevance of antibody reactivities in patients with  Crohn’s disease; Rows corresponding to L1, L4, B3 and A2 were omitted 
because statistically significant differences for a given parameter were not obtained; Positive associations are indicated in bold and negative 
associations in italic; A (Age), L (Location), and B (Behavior) according to Montreal classification; L1 ileal; L2 colonic; L3 ileocolonic, and L4 
upper disease modifier; B1, non-stricturing/non penetrating; B2, stricturing; B3, penetrating behavior 
P  
OR  
95%CI  
IgA  
Anti-MZGP2  
IgG  
Anti- MZGP2  
IgA or IgG  
Anti-
MZGP2  
IgA  
ASCA  
IgG  
ASCA  
IgA or IgG  
ASCA  
(IgA or IgG) ASCA  
or  
(IgA or IgG) Anti-
MZGP2  
(IgA or IgG) ASCA  
&  
(IgA or IgG) Anti-
MZGP2  
x-ANCA  
L2   0.002  0.007  0.0008  <0.0001  <0.0001  <0.0001  0.002   
L3   0.007    
2.3 (1.2, 4.2)  
0.013          
2 (1.2, 3.6)  
0.03         
1.7 (1.1, 2.8)  
0.003      
1.9 (1.2, 3.2)  
0.012      
1.9 (1.2, 3.2)  
 0.001                        
2.8 (1.5, 5.2)  
 
B1     0.033  0.021  0.002   0.005   0.038      
2.3 (1.1, 5.3)  
B2      0.006      
2.3 (1.3, 4)  
 0.005     
2.4 (1.3, 4.6)       
0.001                         
3.1 (1.5, 6.3)                        
  
A1  0.011    
2.3 (1.2, 4.4)  
      0.043 
1.8 (1.0, 3.1)  
 
A3         0.003  0.026  0.015    
Duration   0.018  0.026  <0.0001   0.019  0.008  0.034   
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